RT Book, Section
A1 Chesnutt, Asha N.
A1 Chesnutt, Mark S.
A1 Prendergast, Niall T.
A1 Prendergast, Thomas J.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
SR Print(0)
ID 1175808011
T1 E-cigarette- and vaping product-associated lung injury (EVALI)
T2 Current Medical Diagnosis & Treatment 2021
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260469868
LK accessmedicine.mhmedical.com/content.aspx?aid=1175808011
RD 2022/05/21
AB Key  Clinical  Updates  in  E-cigarette-  and  vaping  product-associated  lung  injury  (EVALI)Diagnosis  of  EVALI  requires  reported  use  of  e-cigarette  or  vaping  products  within  3  months  of  symptom  onset,  compatible  chest  imaging  findings  (bilateral  pulmonary  opacities  on  chest  radiograph,  CT  findings  similar  to  hypersensitivity  pneumonitis,  acute  respiratory  distress  syndrome,  diffuse  alveolar  hemorrhage,  acute  eosinophilic  pneumonia,  lipoid  pneumonia,  giant  cell  interstitial  pneumonia,  and  organizing  pneumonia),  and  an  evaluation  to  exclude  infectious  etiologies.In  hospitalized  patients  with  EVALI,  rapid  improvement  with  corticosteroids  has  been  described.